OVERALL AIMS:

  • Aim 1: To Optimize Diagnostic, Monitoring, and Therapeutic Approaches for African and African American Men. We will develop and test innovative rational-based therapies and define new approaches for therapeutic intervention focused specifically at the situation of African and African American men with prostate cancer.

  • Aim 2: To Generalize Precision Medicine Approaches to African and African American Men. We will identify critical subtypes and biomarkers of disease progression and response, with the goal of developing metrics for personalized medicine and determining the molecular basis of risk in African American men with prostate cancer.

  • Aim 3: To Implement and Disseminate Optimal Therapeutic Approaches to African and African American men with prostate cancer. Planned strategies will encourage and promote the translation of innovative, impactful clinical approaches that can be implemented in communities.

 

These overarching aims will be accomplished through the implementation of three projects:
 

PROJECT 1

  • PIs: Tim Rebbeck (DFCI) and Kosj Yamoah (Moffitt)


Goal: To conduct an in-depth evaluation of the molecular characteristics of PCa from AAM compared with EAM samples to develop biomarkers for AAM that can guide treatment decisions

  1. To identify patients with aggressive disease and fast-track them to more aggressive treatment schedules

  2. To provide actionable targets to develop new effective treatments for this at-risk population
     

PROJECT 2

  • PIs: Grace Lu-Yao (TJU) and William Kevin Kelly (TJU)

  • Co-Is: Jennifer Cullen (Case) and Leonard Gomella (TJU)

 

Goal: To create a PCa nomogram that accounts for an individual’s clinical and tumor characteristics, comorbidities, and tumor biomarkers in order to improve clinical decision-making, management, and outcomes.

  1. To determine the spectrum of somatic genetic alterations in AA castration-resistant PCa

  2. To facilitate the incorporation of salient genetic information into targeted therapeutic trials in AA men with PCa

  3. To provide a comprehensive view of the types of heterogeneity of cancer and immune cells within AA prostate cancer
     

PROJECT 3

  • PIs: Franklin Huang (UCSF), Joshua Campbell (BI), and Gretchen Gignac (BMC)

  • Co-Is: Atish Choudhury (DFCI)

 

Goals:

  1. To determine the spectrum of somatic genetic alterations in AA castration-resistant PCa

  2. To facilitate the incorporation of salient genetic information into targeted therapeutic trials in AA men with PCa

  3. To provide a comprehensive view of the types of heterogeneity of cancer and immune cells within AA prostate cancer

 

 

PARTICIPATING INSTITUTIONS 
AND SITE INVESTIGATORS

 


CONTACT

Please contact the Project Manager, Emily Quach (Emily_Quach@dfci.harvard.edu) with any questions or need additional assistance. 

MADCaP US Resources

WELCOME TO THE MADCaP US HOME PAGE!

MADCaP Network
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215

Supported by Dana-Farber Cancer Institute

MADCaP is grant-funded by the National Cancer Institute

© Copyright 2016-2020 

Dana-Farber Cancer Institute.

Use of MADCaP is subject to our terms of use and our privacy policy.

NCI_Stacked_COLOR.png
img-logo-2x-new.png